Chembio Diagnostics Stock Forecast, Price & News

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

Is Chembio Diagnostics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chembio Diagnostics stock.
View analyst ratings for Chembio Diagnostics or view top-rated stocks.

How has Chembio Diagnostics' stock price been impacted by COVID-19?

Chembio Diagnostics' stock was trading at $3.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CEMI shares have decreased by 35.5% and is now trading at $2.00.
View which stocks have been most impacted by COVID-19.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Chembio Diagnostics.

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) announced its earnings results on Thursday, November, 4th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.05. The firm earned $12.06 million during the quarter. Chembio Diagnostics had a negative net margin of 72.24% and a negative trailing twelve-month return on equity of 86.50%. During the same period last year, the business posted ($0.28) earnings per share.
View Chembio Diagnostics' earnings history.

What price target have analysts set for CEMI?

2 Wall Street analysts have issued twelve-month target prices for Chembio Diagnostics' shares. Their forecasts range from $8.00 to $10.00. On average, they expect Chembio Diagnostics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 350.0% from the stock's current price.
View analysts' price targets for Chembio Diagnostics or view top-rated stocks among Wall Street analysts.

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the following people:

• Richard L. Eberly, President, Chief Executive Officer, CFO & Director
• Paul J. Angelico, Vice President-Operations
• Javan Esfandiari, Chief Science & Technology Officer
• Paul Lambotte, Vice President-Research & Development
• Robert Passas, VP-International Sales & Business Development

Who are some of Chembio Diagnostics' key competitors?

Some companies that are related to Chembio Diagnostics include CTI BioPharma (CTIC), Sensei Biotherapeutics (SNSE), Molecular Templates (MTEM), Matinas BioPharma (MTNB), Clearside Biomedical (CLSD), Avalo Therapeutics (AVTX), Wave Life Sciences (WVE), Ampio Pharmaceuticals (AMPE), Vincerx Pharma (VINC), DURECT (DRRX), Esperion Therapeutics (ESPR), Immunic (IMUX), Antibe Therapeutics (ATBPD), Leap Therapeutics (LPTX) and AVEO Pharmaceuticals (AVEO).
View all of CEMI's competitors.

What other stocks do shareholders of Chembio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK).

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Segall Bryant & Hamill LLC (1.23%), BlackRock Inc. (0.93%), Geode Capital Management LLC (0.68%), Morgan Stanley (0.41%), Citadel Advisors LLC (0.00%) and Newbridge Financial Services Group Inc. (0.22%).
View institutional ownership trends for Chembio Diagnostics.

Which major investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including Segall Bryant & Hamill LLC, Millennium Management LLC, Squarepoint Ops LLC, and Newbridge Financial Services Group Inc..
View insider buying and selling activity for Chembio Diagnostics or view top insider-selling stocks.

Which major investors are buying Chembio Diagnostics stock?

CEMI stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Geode Capital Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Jump Financial LLC, Wolverine Trading LLC, and Signaturefd LLC.
View insider buying and selling activity for Chembio Diagnostics or or view top insider-buying stocks.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $2.00.

How much money does Chembio Diagnostics make?

Chembio Diagnostics has a market capitalization of $60.09 million and generates $32.47 million in revenue each year. The company earns $-25.52 million in net income (profit) each year or ($1.26) on an earnings per share basis.

How many employees does Chembio Diagnostics have?

Chembio Diagnostics employs 355 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is www.chembio.com.

Where are Chembio Diagnostics' headquarters?

Chembio Diagnostics is headquartered at 555 WIRELESS BLVD., HAUPPAUGE NY, 11788.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at (631) 924-1135, via email at [email protected], or via fax at 631-924-2065.